ArticleClinicoEconomics and outcomes research : CEOR2017

Update of the budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial.

Umberto Restelli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.